Courtney Cupples is the Chief Commercial Officer at Abcuro and brings more than 25 years of global experience in commercializing orphan drug medicines for rare diseases. Prior to joining Abcuro, Courtney served as Chief Commercial Officer for Priovant Therapeutics, where she led commercial launch preparation for the company’s oral small molecule, brepocitinib, currently in development for the potential treatment of severe autoimmune diseases. Prior to this, Courtney spent five years at Biohaven Pharmaceuticals where she led commercial strategic planning for the company’s clinical-stage rare disease portfolio focused primarily on neuromuscular conditions. Before Biohaven, she spent nine years at Alexion Pharmaceuticals where she led the launch of Soliris^®(eculizumab) in Latin America, served as leader of the global franchise for the atypical hemolytic uremic syndrome (aHUS) indication for (Soliris^®) and led the global metabolic disease franchise for Strensiq^®(asfotase alfa) and Kanuma^®(sebelipase alfa). Courtney began her career at Genzyme Corporation where she served in various commercial roles over 11 years, driving expansion of the company’s enzyme replacement therapy business in Latin America. Courtney holds a Bachelor of Arts in Sociology & Anthropology from Swarthmore College.

Karen Tubridy is the Chief Operating Officer of Abcuro.  She brings more than 30 years of experience in drug development strategy and operations supporting novel and first-in-class therapeutics. Previously, Karen served as a Chief Development Officer at Verseau Therapeutics, Akebia Therapeutics, and Eleven Bio. She has had responsibility for driving global program strategies to IND, NDA and J-NDA filings. In addition, she has had responsibility for oversight of drug development operations including the build out of core R&D infrastructure and quality systems. Previously, she held senior positions in clinical and regulatory operations at Inspiration Biopharmaceuticals, Taligen Therapeutics (acquired by Alexion) and Syntonix Pharmaceuticals (acquired by Biogen). She held a senior position at AVANT Immunotherapeutics directing several vaccine programs and held positions of increasing responsibility in clinical research and medical affairs at Genetics Institute/Wyeth Pharmaceuticals, where she directed hematology and oncology programs. Karen holds a BS in pharmacy and a PharmD from the Massachusetts College of Pharmacy and Allied Health Sciences.